Addex Therapeutics Ltd. (ADXN) Receivables (2022 - 2024)

Addex Therapeutics' Receivables history spans 3 years, with the latest figure at $26802.9 for Q4 2024.

  • For Q4 2024, Receivables fell 78.46% year-over-year to $26802.9; the TTM value through Dec 2024 reached $26802.9, down 78.46%, while the annual FY2024 figure was $26689.8, 78.28% down from the prior year.
  • Receivables for Q4 2024 was $26802.9 at Addex Therapeutics, down from $124416.0 in the prior quarter.
  • Across five years, Receivables topped out at $557288.0 in Q4 2022 and bottomed at $26802.9 in Q4 2024.
  • The 3-year median for Receivables is $124416.0 (2023), against an average of $236169.0.
  • The largest annual shift saw Receivables plummeted 77.67% in 2023 before it crashed 78.46% in 2024.
  • A 3-year view of Receivables shows it stood at $557288.0 in 2022, then tumbled by 77.67% to $124416.0 in 2023, then plummeted by 78.46% to $26802.9 in 2024.
  • Per Business Quant, the three most recent readings for ADXN's Receivables are $26802.9 (Q4 2024), $124416.0 (Q4 2023), and $557288.0 (Q4 2022).